---
schema_version: "secwatch.filing_event.v1"
accession: "0001847367-26-000004"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:41:17.827357+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alumis reports 2025 net loss $243.3M; Phase 3 envudeucitinib meets endpoints; NDA plan 2H2026

## Summary
- Net loss of $243.3M vs. $294.2M in 2024; revenue $24.1M from Kaken license.
- Cash, cash equivalents and marketable securities $308.5M at Dec 31, 2025.
- Jan 2026 public offering raised $345.1M gross; net proceeds $324.4M extend runway into Q4 2027.
- R&D expenses $386.0M, up 45% YoY, driven by Phase 3 ONWARD program and merger costs.
- NDA for envudeucitinib in plaque psoriasis on track for 2H2026; SLE Phase 2b data expected 3Q2026.

## SEC filing metadata
- accession: 0001847367-26-000004
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/0001847367-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847367-26-000004
- JSON: https://secwatch.observer/filing/0001847367-26-000004.json
- Plain text: https://secwatch.observer/filing/0001847367-26-000004.txt

## Key facts
- Earnings Releases
  ALUMIS INC. reported the year ended December 31, 2025 results: revenue license revenue of $17.4 million and collaboration revenue of $6.7 million, net income Net loss was $243.3 million.
  - Period: the year ended December 31, 2025
  - Revenue: license revenue of $17.4 million and collaboration revenue of $6.7 million
  - Net income: Net loss was $243.3 million
  - Result: reported results
  source text: Revenue included license revenue of $17.4 million and collaboration revenue of $6.7 million for the year ended December 31, 2025, related to the collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. ● Research and development expenses were $386.0 million for the year ended December 31, 2025, compared to $265.6 million for the year ended December 31, 2024. The increase was primarily driven by contract research and clinical trial costs for the envudeucitinib and other programs, including costs to support acceleration of clinical trial activities for the Phase 3 ONWARD clinical program, as well as increased headcount to support development efforts and severance costs, including stock-based compensation expense, related to the merger with ACELYRIN. The year ended December 31, 2024 included a clinical milestone payment of $23.0 million related to the prior acquisition of FronThera. ● General and administrative expenses were $91.9 million for the year ended December 31, 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/0001847367-26-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.